Clinical trials: Carcinoma Liver
Hepatocellular Carcinoma, Chemoembolization, Therapeutic
Contrast-enhanced Ultrasound Evaluation of Chemoembolization
The primary objective of this trial is to evaluate the sensitivity and specificity of 2D and 4D contrast enhanced ultrasound for monitoring transarterial chemoembolization (TACE) response 1-2 weeks and 1 month post treatment as…
- Trial name
- NCT02764801
- Testing
- Ultrasound contrast agent (Contrast-enhanced ultrasound), Logiq E9 Scanner (Contrast-enhanced ultrasound)
- Where
- 3 sites in United States
- Volunteers
- 131 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Liver Cancer, Metastatic Cancer
Chemoembolization in Treating Patients With Primary Liver Cancer or Metastases to the Liver
RATIONALE: Chemoembolization kills tumor cells by blocking the blood flow to the tumor and keeping chemotherapy drugs near the tumor.
- Trial name
- NCT00003907
- Testing
- cisplatin, doxorubicin, mitomycin
- Where
- 37 sites in United States
- Volunteers
- 50 people
- Sponsor
- Eastern Cooperative Oncology Group
Hepatocellular Carcinoma
Combination Chemoembolization and Stereotactic Body Radiation Therapy in Unresectable Hepatocellular Carcinoma
The purpose of this study is to develop better ways to treat liver cancer, known as hepatocellular carcinoma or HCC, while it is still in the liver.
- Trial name
- NCT02513199
- Testing
- SBRT, TACE
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Carcinoma, Hepatocellular
A Randomized, Double-Blinded, Placebo-Controlled Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma
The purpose of the study is Find out if patients receiving Sorafenib will live longer Find out if Sorafenib has any effect on patient reported outcomes Find out if Sorafenib prevents the growth or shrinks liver tumors and / or…
- Trial name
- NCT00492752
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- 23 sites in China, South Korea and 1 more
- Volunteers
- 226 people
- Sponsor
- Bayer
Carcinoma, Hepatocellular
Pegylated Alfa-2b Interferon Therapy of Patients With Hepatitis C-related Cirrhosis and High Liver Cell Proliferation (P02733/MK-4031-085)
This study aims to compare the role of peginterferon α-2b (50 μg/week) vs. control (no treatment) in the prevention of hepatocellular carcinoma, in adult patients with cirrhosis and initial signs of portal hypertension who did…
- Trial name
- NCT00759109
- Testing
- Peginterferon alfa-2b, Observation (no treatment)
- Volunteers
- 150 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma
Cabozantinib and Pembrolizumab for the First-Line Treatment of Advanced Liver Cancer
This phase II trial studies how well cabozantinib and pembrolizumab work for the first-line treatment of patients with liver cancer who are not eligible for local therapy (i.e. advanced stage).
- Conditions
- Advanced Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma
- Trial name
- NCT04442581
- Testing
- Cabozantinib S-malate, Pembrolizumab
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Washington
Hepatocellular Carcinoma, Resectable Hepatocellular Carcinoma
Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer
This phase II trial studies the side effects and how well nivolumab with or with ipilimumab works in treating patients with liver cancer that can be removed by surgery.
- Trial name
- NCT03222076
- Testing
- Ipilimumab, Nivolumab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer, Lung Cancer
Study of Pazopanib and Ixabepilone in Patients With Solid Tumors
This is a Phase I study; dose escalating the combination of pazopanib when taken daily and ixabepilone when administered on day 1 of a 3 week treatment course.
- Conditions
- Breast Cancer, Lung Cancer, Colon Cancer, Pancreatic Cancer
- Trial name
- NCT01012362
- Testing
- Pazopanib, Ixabepilone
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Childhood Hepatocellular Carcinoma, Papillary Thyroid Cancer
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
This phase II trial studies how well sorafenib tosylate works in treating younger patients with relapsed or refractory rhabdomyosarcoma, Wilms tumor, liver cancer, or thyroid cancer.
- Conditions
- Childhood Hepatocellular Carcinoma, Papillary Thyroid Cancer, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Childhood Liver Cancer
- Trial name
- NCT01502410
- Testing
- sorafenib tosylate, pharmacological study, laboratory biomarker analysis
- Where
- 92 sites in United States, Australia and 1 more
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Liver Cancer
Sunitinib Malate (SUO11248) In Subjects W/ Metastatic And/Or Surgically Unresectable Hepatocellular Cancers (HCC)
An open label multi-site phase II clinical trial of dose escalated sunitinib malate given orally once daily on days 1-28 of each 42-day cycle.
- Trial name
- NCT00495625
- Testing
- Sunitinib Malate
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Ewing Sarcoma, PEComa
Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers
This study investigates the safety/toxicity and potential anti-tumor activity of sequential administration of nivolumab and escalating doses of the mammalian target of rapamycin (mTOR) inhibitor nab-rapamycin (ABI-009) in…
- Conditions
- Ewing Sarcoma, PEComa, Epithelioid Sarcoma, Desmoid Tumor
- Trial name
- NCT03190174
- Testing
- Nab-Rapamycin, Nivolumab
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Sarcoma Oncology Research Center, LLC
Carcinoma, Hepatocellular
A Study of Amivantamab Monotherapy in Participants With Previously Treated Advanced Hepatocellular Carcinoma
The purpose of this study is to characterize the preliminary antitumor activity of amivantamab at the recommended dose in participants with previously systemically treated hepatocellular carcinoma (HCC)
- Trial name
- NCT05653427
- Testing
- Amivantamab
- Where
- 13 sites in China
- Volunteers
- 18 people
- Sponsor
- Janssen Research & Development, LLC
Advanced Hepatocellular Carcinoma
A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Hepatocellular Carcinoma
The purpose of this study is to evaluate the efficacy and safety of cabozantinib in Japanese participants with advanced hepatocellular carcinoma (HCC) who have received prior systemic anticancer therapy.
- Trial name
- NCT03586973
- Testing
- Cabozantinib
- Where
- 17 sites in Japan
- Volunteers
- 34 people
- Sponsor
- Takeda
Hepatocellular Carcinoma
A Study of Pembrolizumab and Bavituximab in Patients With Advanced Hepatocellular Carcinoma
This is a non-randomized, open-label, multi-site phase II therapeutic trial of pembrolizumab and bavituximab in patients with locally advanced HCC.
- Trial name
- NCT03519997
- Testing
- Pembrolizumab, Bavituximab
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- David Hsieh
Hepatocellular Carcinoma
Study of Bavituximab, Axitinib, and Avelumab in Advanced Hepatocellular Carcinoma
Across cancer types, immune checkpoint inhibitors have been shown to induce complete response, partial response, and stable disease after initial evidence of radiographic increase in tumor burden.
- Trial name
- NCT05249569
- Testing
- Axitinib, Avelumab, Bavituximab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Texas Southwestern Medical Center
Hepatitis B, Chronic
Efficacy and Safety Study of Tenofovir Disoproxil Fumarate (TDF) in Chinese Chronic Hepatitis B (CHB) Subjects With Advanced Fibrosis & Compensated Cirrhosis
Chronic Hepatitis B infection (CHB) is known as the most frequently identified cause of liver disease that predisposes patients to the development of hepatocellular carcinoma (HCC).
- Trial name
- NCT02224456
- Testing
- Tenofovir disoproxil fumarate
- Where
- 19 sites in China
- Volunteers
- 197 people
- Sponsor
- GlaxoSmithKline
Colon Cancer, Pancreatic Cancer
Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers
Background: Gastrointestinal tumors have a molecule called carbohydrate antigen 19-9 (CA19-9) in the tumors and blood. The agent MVT-5873 was designed to block this molecule.
- Conditions
- Colon Cancer, Pancreatic Cancer, Cholangiocarcinoma, Metastatic Colon Carcinoma
- Trial name
- NCT03801915
- Testing
- MVT-5873, pancreatectomy or hepatectomy
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Cancer Institute (NCI)
Liver Cancer, Liver Neoplasm
Integrated Imaging Strategy to Phenotype Progression of Liver Tumors During and After Chemoembolization
Background: Treatment for liver cancer can include surgery, transplant, and chemotherapy. It can also include other minimally invasive tumor treatments such as transarterial chemoembolization (TACE).
- Conditions
- Liver Cancer, Liver Neoplasm, Hepatocellular Carcinoma, HCC
- Trial name
- NCT02471313
- Testing
- [18F] FMISO
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Hepatocellular Carcinoma
Adjuvant Radiotherapy for Resected Hepatocellular Carcinoma With MVI
Positive micro vascular invasion in early stage hepatocellular carcinoma(HCC) leads to early recurrence after surgery. Adjuvant external radiotherapy will be applied in those patients to see if disease free survival and overall…
- Trial name
- NCT04891874
- Testing
- Stereotactic radiotherapy
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Melanoma, Colon Cancer
Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer
Background: Exome sequencing can identify certain gene mutations in a person's tumor. This can then be used to create cancer treatments.
- Conditions
- Melanoma, Colon Cancer, Gastrointestinal Cancer, Genitourinary Cancer
- Trial name
- NCT03480152
- Testing
- National Cancer Institute (NCI)-4650, a messenger ribonucleic acid (mRNA)-based, Personalized Cancer Vaccine
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)